drugset / Trial / NCT04226170
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.
Timeline
- Start
- 2023-11-08
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ondansetron | Other / unclassified | — | — |
| Background | Pyridostigmine | Small molecule | — | — |